Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorpheniramine Injection for Chronic Inflammatory Skin Diseases
NCT04937101Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of chlorpheniramine in pathological scarring (PS), sarcoidosis and atopic dermatitis (AD) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: The degree of improvement in lesion thickness at 1 year. Status: unknown.
02
Drugs
chlorpheniramine
03
Conditions
pathological scarring (PS)sarcoidosisatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04937101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937101.